When GLP-1 Medication Stops Working: Plateau and Resistance Explained

You started treatment with Wegovy, Ozempic or Mounjaro, and for the first few months the weight came off steadily. Then — it stopped. The scale isn't moving. What's going on? Has the medication stopped working? The answer is more nuanced than a simple yes or no, and it has far more to do with biology than willpower.

What is a weight loss plateau?

A weight loss plateau is a period where your weight remains stable despite continuing your treatment. It is not a sign that the medication has been "used up" or that your body has become immune to it. It's a normal biological response that happens to almost everyone who loses weight — regardless of the method.

Plateaus occur because your body is remarkably good at adapting. When you lose weight, your body burns fewer calories — simply because there's less of you to maintain. On top of that, your metabolism slows in a process called adaptive thermogenesis: the body starts conserving energy because it perceives weight loss as a survival threat.

When does a plateau typically occur?

In the large clinical trials with semaglutide (Wegovy) and tirzepatide (Mounjaro), most participants reached their maximum weight loss between 20 and 60 weeks (roughly 5 to 14 months). For most people, weight loss begins to visibly slow after 6–9 months on a stable dose, and a true plateau is very common after 9–12 months.

It's important to understand: even a plateau is a success. Maintaining a 10–20% weight loss is enormously beneficial for health — it significantly reduces the risk of type 2 diabetes, cardiovascular disease, and joint problems.

What happens in your body?

When the body loses weight, it activates several counter-regulatory mechanisms. Research shows these responses are strong and persistent:

• Metabolic rate falls: For every 10% of body weight lost, resting metabolic rate drops significantly. Your body simply burns fewer calories than expected.
• Ghrelin (the hunger hormone) rises: Your body produces more ghrelin, which sends signals to the brain that you are hungry — even when you've eaten enough.
• Leptin (the satiety hormone) falls: You produce less leptin, which normally signals fullness to the brain. The result is you don't feel as satisfied after meals as you used to.
• Muscle mass decreases: Weight loss involves not just fat but also some muscle tissue — and muscle burns more energy than fat, even at rest.

GLP-1 medications are highly effective at suppressing appetite, but they cannot fully override these deeply ingrained biological adaptations. This is not a lack of willpower — it is nature's resistance to weight loss.

Who doesn't respond to the medication?

The vast majority of users experience meaningful weight loss, but clinical studies show that 10–17% of semaglutide users are "non-responders" — losing less than 5% of their starting weight despite correct use and correct dosing. These individuals are not non-compliant; there are typically biological reasons:

• Type 2 diabetes: People with diabetes lose an average of 9–10% with semaglutide, versus 14–15% for those without. Insulin resistance and diabetes medications play a role.
• Biological sex: Men lose an average of 8–9%, women 14–16%. Hormonal and physiological differences are the likely cause.
• Genetics: Individual variations in GLP-1 receptor sensitivity can mean the medication doesn't signal as strongly in everyone.

Lifestyle and medical factors that can reduce effectiveness

Beyond biological factors, there are circumstances you can influence — and medical conditions your doctor should assess:

• Insufficient sleep: Sleep deprivation raises ghrelin and lowers leptin — exactly the hormones the medication is trying to regulate. Fewer than 7 hours per night can directly undermine your treatment.
• Chronic stress: Elevated cortisol promotes fat storage (particularly around the abdomen) and increases cravings for calorie-dense foods.
• Certain medications: Corticosteroids (e.g. prednisolone), antipsychotics and some antidepressants can cause significant weight gain and work against GLP-1 treatment. Discuss this with your doctor.
• Thyroid function: Hypothyroidism (underactive thyroid) slows metabolism and can significantly stall weight loss. Ask your doctor to check your thyroid levels if progress is very poor.
• PCOS: Polycystic ovary syndrome makes weight loss harder for many women, even on GLP-1 medication, due to insulin resistance and hormonal disruption.
• Dose still too low: If you are still on a low starter dose and have had no side effects, you may not have reached your maintenance dose yet. The titration process can take 4–5 months.

What can you do about a plateau?

A plateau does not mean treatment has failed. Here are evidence-based steps that can help:

1. Increase protein intake: Protein boosts satiety, protects muscle mass during weight loss and requires more calories to digest than carbohydrates or fat. Aim for 1.2–1.6 g of protein per kg of body weight per day.
2. Strength training 2–3 times a week: Muscle burns more energy than fat, even at rest. Resistance training helps preserve muscle mass and can restart your metabolism.
3. Prioritise sleep: 7–9 hours of sleep per night is documented to support weight loss treatment. Good sleep hygiene is an underrated part of the therapy.
4. Manage stress: Mindfulness, regular exercise and social connection can lower cortisol and support weight loss.
5. Review your titration: Talk to your doctor about whether you have reached the right maintenance dose and whether any adjustment is needed.

When should you contact your doctor?

Reach out to your doctor if:

• You have been on your target dose for 3–4 months without achieving at least 5% weight loss
• You suspect an underlying condition (e.g. underactive thyroid, PCOS, depression)
• You are considering switching from semaglutide to tirzepatide — in the head-to-head SURMOUNT-5 trial, tirzepatide achieved average weight loss of 20.2% versus 13.7% for semaglutide
• You are taking other medications that may be working against your weight loss

Any change in treatment or dosing should always be made in consultation with your doctor.

Key takeaways

• A plateau after 6–12 months is normal and biologically expected
• Biological adaptations — not lack of willpower — are the primary cause of plateaus
• 10–17% of users are non-responders, often for biological reasons
• Sleep, stress, diet and exercise have a major influence on treatment effectiveness
• Talk to your doctor if you see no effect at all after 3–4 months on your target dose

Sources

• Ghusn et al. (2024). Semaglutide for weight loss: unanswered questions. Frontiers in Endocrinology.
• Ghusn et al. (2024). Semaglutide for weight loss: unanswered questions. PMC/NCBI.
• Wilding et al. (2022). Weight regain and cardiometabolic effects after withdrawal of semaglutide. PubMed/NEJM.
• Wilding et al. (2021). Once-Weekly Semaglutide in Adults with Overweight or Obesity. NEJM (STEP 1).
• Mayo Clinic. Semaglutide (subcutaneous route).
• NHS England. Weight management injections.